Eli Lilly Total Non-Cash Items 2010-2024 | LLY
Eli Lilly annual/quarterly total non-cash items history and growth rate from 2010 to 2024. Total non-cash items can be defined as the total of all non-cash charges adjusting Net Income on the Cash Flows Statement
- Eli Lilly total non-cash items for the quarter ending December 31, 2024 were $3.613B, a 75.84% increase year-over-year.
- Eli Lilly total non-cash items for the twelve months ending December 31, 2024 were $4.789B, a 32.85% increase year-over-year.
- Eli Lilly annual total non-cash items for 2024 were $3.613B, a 75.84% increase from 2023.
- Eli Lilly annual total non-cash items for 2023 were $2.055B, a 53.14% increase from 2022.
- Eli Lilly annual total non-cash items for 2022 were $1.342B, a 52.03% decline from 2021.
Eli Lilly Annual Total Non-Cash Items
(Millions of US $) |
| 2024 |
$3,613 |
| 2023 |
$2,055 |
| 2022 |
$1,342 |
| 2021 |
$2,797 |
| 2020 |
$1,053 |
| 2019 |
$-1,795 |
| 2018 |
$4,671 |
| 2017 |
$2,615 |
| 2016 |
$2,598 |
| 2015 |
$1,695 |
| 2014 |
$2,393 |
| 2013 |
$1,443 |
| 2012 |
$1,267 |
| 2011 |
$1,638 |
| 2010 |
$1,973 |
| 2009 |
$964 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$796.425B |
$45.043B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
